Human Cerenkov Luminescence Imaging of Superficial In-Vivo Tumours after Administration of 18F-FDG

Human Cerenkov Luminescence Imaging of Superficial In-Vivo Tumours after Administration of 18F-FDG - Feasibility of In-vivo Human Cerenkov Imaging

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON42215

Enrollment

Registered

2015-04-13

Start date

2015-04-22

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer malignant tumours

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients, older than 18 years, who will receive and 18F-FDG PET-CT scan and have a superficial tumour,

Exclusion criteria

Exclusion criteria: Patient younger than 18 years. Patients with a melanoma with a high melanin level.

Design outcomes

Primary

Measure	Time frame
The main question is whether we ara able to image the uptake of 18F-FDG in a human tumour, in-vivo, with a stand alone EMCCD camera. The primary study parameter is if we can subjectively distinguish the tumour from the background.	—

Secondary

Measure	Time frame
Secondary study parameters are the signal to noise ratio between the tumour and healthy tissue. With that we take the actual uptake and the depth of the tumour into account.	—

Countries

Netherlands

Outcome results